Literature DB >> 8497916

Testing cervicography and cervicoscopy as screening tests for cervical cancer.

S Cecchini1, R Bonardi, A Mazzotta, G Grazzini, A Iossa, S Ciatto.   

Abstract

AIMS AND
BACKGROUND: Suboptimal sensitivity is currently reported for Pap test in screening for cervical cancer. Colposcopy is known to be more sensitive than cytology but its use as a screening test is not possible due to costs and complexity. Screening by cervicography has been suggested as a compromise being less costly and feasible. The present study evaluates the feasibility of screening by cervicography and cervicoscopy (naked eye examination of the cervix after acetic acid lavage) on a consecutive screening series.
METHODS: Cervicography and cervicoscopy were performed by the smear taker in subjects consecutively attending a screening clinic. Women with abnormal cytology (atypia or more severe lesion) and/or abnormal cervicography or cervicoscopy (acetowhite lesion) underwent colposcopic assessment. The three screening methods were compared according to positivity rate, CIN 2-3 detection rate and positive predictive value.
RESULTS: 2105 consecutive subjects were screened. Positivity rate was 3.8%, 15.3% or 25.4% for cytology, cervicography or cervicoscopy, respectively, 486 of 555 women attended the assessment phase, 281 directed biopsies were performed and 8 CIN 2-3 lesions were detected. Cytology, cervicography and cervicoscopy, detected 5.5, or 7 of 8 CIN 2-3 lesions, respectively. The positive predictive value was 0% for cytologic atypia, 25% for cytologic SIL, 1.75% for cervicography and 2.05% for cervicoscopy. Detecting one CIN 2-3 lesion at cytology cost $5,543. The cost per each additional cytologically negative CIN 2-3 lesion detected at cervicography or cervicoscopy was $12,947 or $3,916, respectively.
CONCLUSIONS: The study confirms the limited sensitivity of cytology for CIN 2-3. The association of cervicography was not cost effective. Cervicoscopy was poorly specific but increased the detection rate of CIN 2-3 at relatively low costs. Cervicoscopy is worth further evaluation as a screening test.

Entities:  

Mesh:

Year:  1993        PMID: 8497916     DOI: 10.1177/030089169307900104

Source DB:  PubMed          Journal:  Tumori        ISSN: 0300-8916


  5 in total

1.  Cervical cancer prevention program in Jakarta, Indonesia: See and Treat model in developing country.

Authors:  Laila Nuranna; Mohamad Farid Aziz; Santoso Cornain; Gatot Purwoto; Sigit Purbadi; Setyawati Budiningsih; Budiningsih Siregar; Alexander Arnold Willem Peters
Journal:  J Gynecol Oncol       Date:  2012-07-02       Impact factor: 4.401

2.  Evaluation of visual inspection as a screening test for cervical cancer.

Authors:  R Wesley; R Sankaranarayanan; B Mathew; B Chandralekha; A Aysha Beegum; N S Amma; M K Nair
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

3.  Visual inspection after acetic acid (VIA) is highly heterogeneous in primary cervical screening in Amazonian Peru.

Authors:  Maribel Almonte; Catterina Ferreccio; Silvana Luciani; Miguel Gonzales; Jose M Delgado; Carlos Santos; Manuel Alvarez; Jack Cuzick; Peter Sasieni
Journal:  PLoS One       Date:  2015-01-30       Impact factor: 3.240

4.  Visual inspection with acetic acid as a cervical cancer test: accuracy validated using latent class analysis.

Authors:  Lynne Gaffikin; John A McGrath; Marc Arbyn; Paul D Blumenthal
Journal:  BMC Med Res Methodol       Date:  2007-07-31       Impact factor: 4.615

5.  Age-Related Changes in the Fraction of Cervical Intraepithelial Neoplasia Grade 3 Related to HPV Genotypes Included in the Nonavalent Vaccine.

Authors:  Luca Giannella; Giovanni Delli Carpini; Jacopo Di Giuseppe; Sonia Prandi; Dimitrios Tsiroglou; Andrea Ciavattini
Journal:  J Oncol       Date:  2019-11-06       Impact factor: 4.375

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.